CN105727253A - Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof - Google Patents
Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof Download PDFInfo
- Publication number
- CN105727253A CN105727253A CN201610265250.7A CN201610265250A CN105727253A CN 105727253 A CN105727253 A CN 105727253A CN 201610265250 A CN201610265250 A CN 201610265250A CN 105727253 A CN105727253 A CN 105727253A
- Authority
- CN
- China
- Prior art keywords
- liver
- coarse powder
- granule
- poria
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 136
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 title abstract description 9
- 231100000331 toxic Toxicity 0.000 title description 4
- 230000002588 toxic effect Effects 0.000 title description 4
- 229920002261 Corn starch Polymers 0.000 claims abstract description 21
- 239000008120 corn starch Substances 0.000 claims abstract description 21
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- 239000000843 powder Substances 0.000 claims description 63
- 239000008187 granular material Substances 0.000 claims description 55
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 48
- 235000010469 Glycine max Nutrition 0.000 claims description 48
- 244000068988 Glycine max Species 0.000 claims description 31
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 31
- 229920001542 oligosaccharide Polymers 0.000 claims description 29
- 150000002482 oligosaccharides Polymers 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 25
- 239000004471 Glycine Substances 0.000 claims description 24
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 23
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 23
- 229960004999 lycopene Drugs 0.000 claims description 23
- 239000001751 lycopene Substances 0.000 claims description 23
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 23
- 235000012661 lycopene Nutrition 0.000 claims description 23
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000011321 prophylaxis Methods 0.000 claims description 17
- 230000002596 correlated effect Effects 0.000 claims description 16
- 238000004140 cleaning Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000004806 packaging method and process Methods 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 244000197580 Poria cocos Species 0.000 claims description 5
- 235000008599 Poria cocos Nutrition 0.000 claims description 5
- 238000005253 cladding Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000007598 dipping method Methods 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000008595 infiltration Effects 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 238000005304 joining Methods 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 38
- 239000003814 drug Substances 0.000 abstract description 30
- 208000010706 fatty liver disease Diseases 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 17
- 208000004930 Fatty Liver Diseases 0.000 abstract description 16
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 16
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 6
- 230000029142 excretion Effects 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 59
- 210000004369 blood Anatomy 0.000 description 56
- 239000000243 solution Substances 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 102100040247 Tumor necrosis factor Human genes 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000035568 catharsis Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 10
- 208000019423 liver disease Diseases 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 235000019640 taste Nutrition 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000003908 liver function Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000001865 kupffer cell Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010014080 Ecchymosis Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- -1 flavone compound Chemical class 0.000 description 4
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030302 Oliguria Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058117 Ocular icterus Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 2
- 229930016920 cichoric acid Natural products 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 2
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229930193551 sterin Natural products 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000370738 Chlorion Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 210000004061 pubic symphysis Anatomy 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000003032 wing Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition for protecting liver, clearing toxin, preventing and treating liver and related metabolic diseases, which comprises the main materials of 200; the auxiliary materials comprise 5 parts of edible corn starch and 4 parts of sodium carboxymethyl cellulose, 6 parts of the auxiliary materials. The invention also provides a preparation method of the composition. The formula of the invention adopts natural traditional Chinese medicine materials with food and medicine homology, is supplemented with nutrient substances, has scientific compatibility, promotes medicine excretion, protects the liver, improves the function of liver cells, carries out non-medicine intervention on the problems of fatty liver and related metabolic systems, avoids secondary damage to the liver caused by medicine treatment by food and medicine homology, and achieves the effect of 'clearing liver and protecting liver without damaging the liver'.
Description
Technical field
The present invention relates to field of health care products, a kind of protect the liver detoxicating prophylactic treatment liver and the group of correlated metabolism diseases
Compound and preparation method thereof.
Background technology
Chinese medicine is mainly reflected in the following aspects to the understanding of liver physiological function.
1, main catharsis and harmonizing the functional activities of vital QI: under normal circumstances, liver is dirty with other to ensure itself according to its property reaching catharsis exactly
The normal activity of internal organs.Catharsis function embodiment exists: one is to adjust spirit to go out to consider.The traditional Chinese medical science thinks that the spiritual feelings will of people has close with liver
The relation cut, " Plain Questions LINGLAN secret allusion quotation opinion " is said: " liver person's organ of general, consider and here "." declaring five gas opinions " is also said: " liver
Hide soul ", " considering " and " soul " is all the reflection of spirit feelings will, " Ling Shu Miraculous Pivot or Divine Axis itself " piece cloud: " deficiency of liver-QI is then feared, actually anger ",
Tang Rongchuan says: " night, then soul was attributed to liver and for sleeping." these discussions all reflect the spiritual feelings will of people and the relation of liver, liver catharsis
Normally, mechanism of qi is adjusted and is reached, then spirit is smooth happy, and the change in terms of its normal manner then causes mind, in turn, any feelings will are lost in catharsis
Stimulate and the most all may result in the pent-up of irritability and against random, the two reciprocal causation.Simultaneously as depression and stagnation of QI, blood often can be caused to be subject to
Resistance, qi depression to blood stasis, or be that QI and blood is inverse disorderly." Plain Questions vital QI of the body connecting with natural QI opinion " is said: " excessive anger leading to segregation of QI from the configuration and blood stagnating in the upper part of the body make people
Emotional syncope." clinical findings depression of liver-QI person has two side of body distending pains, uncomfortable in chest smooth more, women then has the phenomenons such as menoxenia, all illustrates
The catharsis effect of liver and the relation of QI-blood circulation.It two is facilitating digestion, to help absorption, through cloud: " food gas enters stomach, the spleen transporting essential substances to the liver ",
What digestive and absorptive functions was movable is normally carried out needing the secretion of the lifting of QI of the spleen and stomach and bile, and taste lift and the secretion of bile
Have to rely on again the normal catharsis of liver, if catharsis imbalance arises that corresponding gastrointestinal symptom, as vexed in inappetence, gastral cavity
Abdominal distention or diarrhea with loose stool etc..
2, main store blood and regulate blood fortune: " six joint hide as opinion " say: " liver person ... its China at pawl ... with hemopoietic gas, " " plain
Ask the five internal organs generation " say: " old friend sleeping and blood is attributed to liver ", Lee stile " Elementary Medicine " also mention " the dynamic then blood of people runs all warps,
People is quiet, and blood is attributed to liver ", these are all regulation effects liver being described for blood volume.Blood keeps certain at human body and weighs,
For the needs of body, when human body carries out aggravating activities or is engaged in other activities daytime, body needs blood volume the most, and works as night
When sleep or rest, then body needs blood volume to reduce accordingly.When needing blood volume many, liver just discharges the excess blood of storage;Need blood volume
Time few, the most unnecessary blood volume returns again liver.Ancients think that liver is the viscus of storing blood, this physiological process of the store blood homergy to human body
It is very important, so Tang Rongchuan says: " always controlling all mass formed by blood stasis nothing more than reason liver also ", adds: " person of enriching blood with tonifying liver is always
Want ".
3, nourishing muscle and tendon arteries and veins and fill profit onyx: through cloud: " food gas enters stomach, and the spleen transporting essential substances to the liver, excess of QI is in muscle ", " Plain Questions innocence in ancient times opinion "
Also say: " irritability declines, the tendon being unable to move ".Visible, muscle arteries and veins be rely on liver moisten support could maintain its normal function.Lee stile says:
" person all biceps of moving are done, liver nourishing muscle and tendon." liver blood abundance, muscle arteries and veins obtains it and moistens, the most strong and powerful, bends and stretches flexibly, otherwise just
There will be biceps feeble and exhausted, extremity are aching and limp unable, and the tired body of body is lazy, is frequently seen these symptoms in hepatopathy.
4, liver is upper by blood supports two mesh: the traditional Chinese medical science thinks that liver is in close relations with mesh, through cloud: " normal vision relying on sufficiency of liver-blood ", " Ling Shu Miraculous Pivot or Divine Axis arteries and veins
Degree opinion " also say: " liver-QI being connected with eyes, liver and then mesh can debate the five colors ".Deficiency of liver-blood then poor vision, dim-sighted, bitterly clinically
Swollen, dry and astringent, " gas becomes big opinion " is sayed that " edema with the liver involved is by strongly fragrant ... conjunctival congestion with ophthalmalgia all infectionss " then refers to the oculopathy caused by flaming up of liver-fire, it is seen that liver
Being the closest with the relation of two mesh, so ancients' meaning " liver opening at eye ", the traditional Chinese medical science is recognized very early and is controlled with animal livers
Treating blindness is also good example.
In a word, liver just because of possessing above-mentioned physiological function, the property of its fluent nature of guarantee, lift mechanism of qi, have enough to meet the need QI and blood,
Facilitating digestion absorbs, and maintains the nutrition of muscle arteries and veins muscle, and these theories have important directive significance for the medication of hepatopathy.
The Overall View of the traditional Chinese medical science is thought, viscera QI and blood is an organic whole, ensures its physiology by mutually coordinated and restriction
Completing of function, liver is as the same.For liver, its normal physiological function depends on the nourishing of kidney water, making moist of nutrient blood, lung
The restriction of gold, the cultivation of spleen soil, then it reaches property of smooth cyclopentadienyl in side, must be soft body, for anosis liver, if four mistake one,
Holding concurrently or disorder of QI and blood, the most variable raw disease, the catharsis week rotating function of liver contributes to again the lifting of taste mechanism of qi, the disappearing of diet simultaneously
Change and absorb, lung qi and a surname sends out and compress, the excretion of bile and the turnover of QI and blood, they are the organic wholes of a vital movement,
Common coordination, maintains the balance of internal organs QI and blood.
For modern medical theory, liver has following functions.
One, metabolic function: 1. carbohydrate metabolism: becoming glucose after starch in diet and carbohydrate digestion through intestinal absorption, liver will
Its synthesis liver glycogen storage gets up;When body requirement, hepatocyte can be that glucose utilizes for body hepatic glycogenolytic again.②
Protein metabolism: liver is the unique synthetic organ of human albumin;Globulin, pheron and plasma protein beyond γ ball egg
Generation, maintain and regulate will liver participate in;The process of amino acid metabolism such as desamination reaction, urea synthesis and ammonia is all liver
Carry out in dirty.3. lipid metabolism: the synthesis of fat and release, fatty acid decomposition, ketoplasia and oxidation, C/PL
Synthesis, lipoprotein synthesis and transport etc. all carry out in liver.4. vitamin metabolism: many vitamin such as A B C D and K
Synthesis with store all closely related with liver.Liver obvious impaired time to there will be vitamin metabolism abnormal.5. hormone metabolism: liver
The inactivation of dirty participation hormone, may occur in which gonadal hormone disturbance when liver function long-term damage.
Two, bile generates and excretion: bilirubinic picked-up, combines and drains, and generation and the excretion of bile acid are all undertaken by liver.
Hepatocyte manufactures, the bile of secretion, is transported to gallbladder through bile duct, and gallbladder drains into small intestinal after concentrating, help fat digestion and
Absorb.
Three, Detoxication: more produced harmful wastes and external poisonous substance, toxin, the generation of medicine during body metabolism
Thank and catabolite, all at liver detoxification.
Four, immunologic function: liver is maximum reticuloendothelial cell phagocytosis system, and it can be by swallowing, isolating and eliminate invasion
Various antigens with interior life.
Five, coagulation function: almost all of thrombin is all manufactured by liver, liver is in human body blood coagulation and two systems of anticoagulant
Dynamic equilibrium plays important regulation effect.The order of severity that liver function is destroyed often is paralleled with the degree of blood coagulation disorders, clinically
Some liver cirrhosis patient common causes hemorrhage even dead because of hepatic failure.
Six, other: liver participate in the regulation of human body blood volume, the generation of heat and water, the regulation of electrolyte.Such as liver injury
Time to sodium, potassium, ferrum, phosphorus, etc. electrolyte Imbalance, it can be common that the retention in vivo of water sodium, cause edema, ascites etc..
But, along with the pollution of environment, bad living habit and the damage of chemicals, the sickness rate of hepatopathy is more and more higher.
Hepatopathy includes acute hepatitis, chronic hepatitis, fatty liver disease, alcoholic liver disease, autoimmune liver disease, liver cirrhosis and constitutional
The multiple disease such as hepatocarcinoma, is that threat human health is one of principal disease now.China 1-59 year population hepatitis B surface antigen
Carrying rate is 7.18%, and c-hepatitis antibody positive rate is 3.2%, existing Chronic Patients with HBV Infection about 93,000,000 people, the most slowly
Property hepatitis B patient about 20,000,000 example, recently as growth in the living standard, fatty liver, the patient of alcoholic liver disease get over
Come the most.
China is the big country that hepatopathy is occurred frequently, and the medical expense paid because of various hepatic disease every year is up to 50,000,000,000 yuans.
The fatty liver that chemical liver injury and a variety of causes cause becomes the common disease that China is the most occurred frequently.Epidemiological study shows
Chinese's pathogenesis of fatty liver rate is about 22-25%, and its sickness rate is gradually increasing along with the raising of people's living standard.Such as clinical
Epidemiological study shows: the pathogenesis of fatty liver rate that Shandong Province's population chemical liver injury and a variety of causes cause is about 33-35%,
The pathogenesis of fatty liver rate that Beijing's population chemical liver injury and a variety of causes cause is about 25%, and Shanghai Population chemical liver damages
Injure the pathogenesis of fatty liver rate that a variety of causes causes and be about 20%, the fat that Shenzhen's population chemical liver injury and a variety of causes cause
Fat liver sickness rate is about 17%.If hepatocellular degeneration moderate or severe fatty liver are treated not in time, in 10 years, develop into liver fiber
Changing and the ratio of liver cirrhosis is up to 70%, the patient with liver cirrhosis of about 20-30% develops into hepatocarcinoma patient the most at last.
Being three points of poison of medicine, liver itself can be caused secondary injury by common pharmacotherapy.
Patent of invention " a kind of compound recipe for liver protecting and preparation method and application " (Publication No. CN 101480442A) is public
Open one to be made up of Herba Taraxaci, Pollen Pini, Flos Lonicerae, Poria, Fructus Gardeniae, Radix Puerariae, vitamin C, zinc gluconate,
There is the liver protecting, recover liver function, improve the effect of liver detoxification.But Herba Taraxaci heavy dose of in this prescription and Fructus Gardeniae taste
Bitterness is trembled with fear, and injures one's stomach, and insufficiency of the spleen loose stool person should not use, the most cold and cool for whole prescription.But, the relation of mutual promotion between the five internal organs,
The raw heart of liver is exactly wood generating fire, if blood stored in the liver is with the heart that helps;The raw spleen of the heart is exactly fire generating earth, and the yang-energy such as the heart can ask spleen;The raw lung of spleen is just
Being earth generating metal, the vital essence such as spleen transporting and transforming nutrients from foodstuff can be with lung benefiting;The raw kidney of lung is exactly metal generating water, then functional activities of the body fluid as respectful in normal lung-QI descending as a means of
Kidney;The raw liver of kidney is exactly water generating wood, if kidney storing essence is to nourish cloudy blood of liver etc..Restriction or checking relation in five elements relation between the five internal organs: lung (golden)
Clear respectful decline, can suppress the rising of liver (wooden) sun, i.e. metal restricting wood;The bar of liver (wooden) reaches, and can dredge the heap soil or fertilizer over and around the roots of purgation of spleen excess (native)
Stagnant, i.e. Wood restricts earth;The transporting of spleen (native), is possible to prevent spreading unchecked of kidney (water) water, i.e. earth restricting water;Cloudy upper of kidney (water)
Ji, can restrict the heart (fiery) yang hyperactivity strong, i.e. water restricting fire;The heart (fiery) sun heat, can restrict lung (golden) the most respectful too,
I.e. fire restricting metal.Therefore, this prescription universality is strong, and has damaged taste after taking.
Summary of the invention
According to above-mentioned weak point, it is an object of the invention to provide a kind of gentleness, adaptable protect the liver detoxicating prophylactic treatment
Compositions of liver and correlated metabolism diseases and preparation method thereof.
For achieving the above object, technical program of the present invention lies in: one protects the liver detoxicating prophylactic treatment liver and correlated metabolism disease
Sick compositions, according to the mass fraction, its major ingredient be Radix Puerariae 200-250 part, Poria 200-220 part, Herba Taraxaci 50-60 part,
Radix Glycyrrhizae 40-50 part, Herba Cichorii 160-180 part, soybean oligo saccharide 5-6 part, soy peptide powder 10-15 part, glycine 5-8 part, kind
Lycopene 2-3 part;Its adjuvant is edible corn starch 5-6 part, sodium carboxymethyl cellulose 4-6 part.
Preferably: described Radix Puerariae, Herba Taraxaci are handled as follows:
(1) Radix Puerariae, Herba Taraxaci are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) weigh the Radix Puerariae coarse powder of 200-250 mass fraction and the Herba Taraxaci coarse powder of 50-60 mass fraction, with solid-liquid ratio be
It is the ethanol water of 40-60% that the ratio of 1:5-10 adds volumetric concentration, ultrasonic immersing 6-8h at a temperature of 40-60 DEG C, filters;
(3) filtering residue is taken, the ratio addition volumetric concentration ethanol water as 40-60% with solid-liquid ratio as 1:1-2,40-60 DEG C
At a temperature of ultrasonic immersing 6-8h, filter, twice filtrate merged, is evaporated to without ethanol;
(4) solution is dialysed, take filtrate and be spray-dried, obtain Radix Puerariae, Herba Taraxaci extract.
Preferably: described Poria, Radix Glycyrrhizae are handled as follows:
(1) Poria, Radix Glycyrrhizae are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) the Poria coarse powder of 200-220 mass parts and the Radix Glycyrrhizae coarse powder of 40-50 mass fraction are weighed, with solid-liquid ratio as 1:5-8
Ratio add pure water, at 45-65 DEG C heated at constant temperature soak 20-30min, heated and boiled 20-30min, filter;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:1-2 adds pure water, and at 45-65 DEG C, heated at constant temperature soaks 20-30min,
Heated and boiled 20-30min, filters, and continues to be heated to boiling, and be stirred continuously after twice filtrate being merged, and makes Poria, sweet
Grass fluid extract is standby.
Preferably: described Herba Cichorii is handled as follows:
(1) Herba Cichorii is cleaned, pulverize after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) joining in container by Herba Cichorii coarse powder, the ratio with solid-liquid ratio as 1:0.8-1 adds 70% ethanol solution, and stirring is all
Even, moistening airtight standing 1-2h;
(3) the Herba Cichorii coarse powder after infiltration is transferred in percolator, suitably presses, after dipping 24-36h, with 1-3ml/min's
Rate collection extracting solution;
(4) by extracting solution concentrating under reduced pressure, until without ethanol;
(5) concentrate, be dried, obtain Herba Cichorii extract.
The present invention also provides for protecting the liver the preparation technology of the compositions of detoxicating prophylactic treatment liver and correlated metabolism diseases, including as follows
Step:
(1) weigh: weigh soybean oligo saccharide 5-6 part, soy peptide powder 10-15 part, glycine 5-8 part, lycopene 2-3
Part, edible corn starch 5-6 part, sodium carboxymethyl cellulose 4-6 part, individually deposit;
(2) pelletize: Radix Puerariae and Herba Taraxaci extract, Poria cocos and liquorice fluid extract, Herba Cichorii extract move into efficient wet granulator
After middle mix homogeneously, add soy peptide powder, glycine, lycopene, sodium carboxymethyl cellulose, again mix homogeneously, make
Granule;
(3) cladding: add soybean oligo saccharide, edible corn starch after step (2) makes granule, by soybean oligo saccharide
It is evenly coated at granule appearance with edible corn starch;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Radix Puerariae sweet in the mouth in above-mentioned prescription, pungent, cool in nature, return spleen, stomach, lung, bladder warp, have relieving muscles diaphoresis, invigorating YANG QI to promote eruption, solve
Effect that heat is promoted the production of body fluid.For treating diarrhea due to hypofunction of the spleen, calentura is thirsty, cure mainly fever caused by exogenous pathogens, and pain of the head and nape is strong, measles without adequate eruption,
The diseases such as epidemic febrile disease is thirsty, quenches one's thirst, alcoholism, obstruction of qi in the chest and cardialgia.Often food Amylum Puerariae Radicis can regulate function of human body, health invigorating, improves body
Resistance against diseases, anti-ageing prolongs life, vigor of remaining youthful forever.Modern medicine study, Radix Puerariae flavone has cancer-resisting and estrogen-like is made
With, women skin care can be promoted, especially obvious to middle-aged women and menopausal women face-nourishing health-care effect.The main component of Radix Puerariae is
Starch, contains the flavone compound of about 12% in addition, and including Semen sojae atricolor (Semen Glycines) glycoside, daidzein, puerarin etc., more than 10 plant;
And containing daucosterol, aminoacid, Coumarins etc.;Also have protein, aminoacid, sugar and the ferrum of needed by human, calcium,
The mineral such as copper, selenium, is all-ages famous and precious tonic, has the good reputation of " Radix Ginseng in thousand "." wound as far back as Han dynasty Zhang Zhongjing
Cold opinion " in just have " GEGEN TANG " this famous prescription, be still the important side of inducing sweat so far." book on Chinese herbal medicine justice " meaning Radix Puerariae "
The gas of taste sun clearly can be developed ".
Poria sweet in the mouth, light, property is put down, GUIXIN, lung, spleen, kidney channel, for edema oliguria, and phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, just
Diarrhea with loose stool is rushed down, irritability, palpitation with fear insomnia.Ancients' Poria is called " god's medicine when four ", because its effect is widely, regardless of four
Season, by it with various compatibility of drugss, the coldest, temperature, wind, wet all diseases, effect of its uniqueness can be played.Modern medicine grinds
Studying carefully, Poria energy enhancing human body immunity function, pachyman has notable antitumor and protects the liver dirty effect.
Soybean oligo saccharide is the general name of solubility saccharic in Semen sojae atricolor, and main component refers to sucrose (disaccharidase), the cotton that monosaccharide number is 3-4
Son sugar (trisaccharide) and stachyose (tetrose) etc..The effect of soybean oligo saccharide has: 1, the clean intestinal of relieving constipation: constipation patient be mostly because of
Enteral lacks caused by bacillus bifidus.Especially old people.With age.Enteral bacillus bifidus gradually decreases and easily suffers from
Constipation.Test proves, Healthy People absorbs 3 grams of soybean oligo saccharide every day, just can promote bifidobacterium growth, produces defecating feces excretion.
Soybean oligo saccharide can also promote that excretion is accelerated in enterokinesia.2, bacillus bifidus propagation in intestinal is promoted: prove through experimentation, every day
Taking in 10-15 gram of soybean oligo saccharide, after 17 days, bacillus bifidus can be increased to 45% by original 0.99%.Double in intestinal
Discrimination bacillus is particularly easy to utilize soybean oligo saccharide, produces acetic acid and lactic acid and some phage speciess, thus suppresses exogenous and cause a disease
Bacterium and enteral are because there being the propagation of Putrefying bacteria: bacillus bifidus, also by phosphatidic acid and intestinal mucosal surface, forms one layer and has protection
The biology of effect, envelope barrier, thus prevent harmful microbe invasion and surely grow.3, serum cholesterol is reduced: bacillus bifidus
Directly affect and disturb the activity of p-footpath base-p-methyl glutaryl enzyme A reductase, it is suppressed that the synthesis of cholesterol, make serum gallbladder
Sterin reduces.4 and the liver protecting: long-term soybean oligo saccharide of taking in can reduce the generation of internal toxic metabolite material, alleviates liver
The burden of removing toxic substances, so also have certain effect in terms of preventing and treating hepatitis and prevention liver cirrhosis.5, the life of enteral corrupt substance is suppressed
Become: prevent and treat constipation and diarrhea.
Herba Taraxaci bitter but sweet flavor, property is flat to be slightly cold, and enters liver, stomach warp, has heat-clearing and toxic substances removing, effect of diuresis eliminating stagnation, cure mainly acute breast
Adenitis, lymphadenitis, scrofula, furuncle carbuncle toxin, acute conjunctivitis, cold, fever, acute tonsillitis, acute bronchitis,
Gastritis, hepatitis, cholecystitis, urinary tract infection.Modern study shows, Herba Taraxaci herb containing taraxasterol, choline, inulin,
Pectin etc., have antibacterial, the effect of antitumor, function of gallbladder promoting.
Radix Glycyrrhizae is the root and rhizome of herbaceos perennial Radix Glycyrrhizae, and nature and flavor are sweet flat, GUIXIN, lung, spleen, stomach warp.Tool invigorating the spleen and replenishing QI,
Nourishing the lung to arrest cough, relieving spasm to stop pain, the merit of the mitigation property of medicine, its effective ingredient is glycyrrhizin, enoxolone, 4',7-Dihydroxyflavanone, Radix Glycyrrhizae
Polysaccharide is one of Chinese herbal medicine of commonly using clinically.Radix Glycyrrhizae also has antiinflammatory, anti-allergic effects, and the throat of inflammation and trachea can be protected to glue
Film.Radix Glycyrrhizae extractum and glycyrrhizic acid have the Detoxication of similar glucuronic acid to some poisonous substance.Subacid contained by Radix Glycyrrhizae can block cause
The effect of cancer thing induced tumor growth.
Herba Cichorii mildly bitter flavor, salty, cool in nature, return spleen, liver, wing, Guang warp, there is liver heat removing function of gallbladder promoting, invigorating the stomach and promoting digestion, inducing diuresis to remove edema
Effect, for jaundice due to damp-heat, lack of appetite of having a stomachache, edema oliguria.Chicoric acid is one of immune active ingredient particularly important in Herba Cichorii,
Modern medicine study shows, chicoric acid has enhancing immunologic function and the effect of antiinflammatory, and can suppress hyaluronidase, protects glue
Former albumen is from the impact of the free radical that may result in degraded.
Soy peptide powder be a kind of be made up of 2-6 aminoacid, molecular weight is at the hybrid peptide product of 200-800Dalton.Soybean peptide
Powder has perfect nutritive value, quickly supplements the whole protein nutrition of needed by human body, improves immunity;Can quickly repair flesh
Meat damage, promotion wound healing;Regain one's strength, strengthen muscle strength, improve motor capacity;Reduce pathologic exception leukocyte
Increase, improve the mental status of old people, slow down aging;Regulation reduces blood fat, blood pressure, cholesterol;Antioxidation, beauty treatment;
Improve sleep;Sport people post exercise muscular soreness can be alleviated, strengthen exercise tolerance, improve motor capacity;To α in human body-
Glucosidase has slow inhibitory action, glucose in energy decomposer rapidly, when being used together with other carbohydrates and saccharide,
Do not affected by amount of insulin secretion, the effect that suppression blood glucose rises rapidly can be played;Soybean protein through special biological enzyme action
Many Toplink stimulate the secretion of internal thyroxin, promote the bile acidification of cholesterol, reduce the intestinal absorption to cholesterol, and
It is promoted to excrete with feces;Soybean protein polypeptide through special biological enzyme action can suppress Angiotensin-Converting (ACE)
Activity.ACE is a kind of carboxylic dipeptidase, and angiotensin I generates the liter blood pressure bioactive peptide that activity is the strongest under the effect of ACE
Angiotensin, the latter's vasoactive smooth muscle, causes vasoconstriction, makes increasing of blood pressure persistence.Suppress as ACE
The soybean peptide of agent, it is possible to reduce the formation of angiotensinⅡ, anti-hemostatic tube end-contraction, reach the purpose of blood pressure lowering.
Glycine is the most basic material constituting protein, and in the composition of human body cell, protein accounts for the 50% of dry cell weight.
The constituent of the various enzymes of various biochemical reactions in protein or participant's health.Therefore, glycine is that human body composition must not
The composition that can lack.The effect of glycine is as follows: 1, reduces the cholesterol concentration in blood, prevents and treats hypertension;2, blood is reduced
In blood glucose value, prevent and treat diabetes;3, blood clotting, thrombosis can be prevented and treated;4, improve muscle vitality, prevent hyperchlorhydria.Separately have
Research shows, glycine can be stoped and exhausted ATP by anti-histanoxia and effectively protect renal proximal tubules and hepatocyte,
Glycine can also alleviate liver reperfusion injury by microcirculation in promoting liver.The major pathologic features of fatty liver is hepatocyte fat
Degeneration and necrosis, wherein liver inner stellate cell (Kupffer cell) produces the cytokine of release, such as tumor necrosis factor (TNF-
α) play a major role, vivo oxidation reducing condition disequilibrium, when producing excessive free radicals, (including ROS, NOS etc.),
In blood, level of endotoxin (such as LPS) is significantly raised, activates Kupffer cell release TNF-α in liver.Recently research have indicated that,
Glycine protection hepatocyte, the mechanism stoping Kupffer cell release TNF-α is that it is thin that glycine can activate open Kupffer
In after birth glycine mediation chloride channel (Glycine-gated Chloride Channel), increase Chlorion influx (raise 2~
3 times), make cell membrane polarity raise, stabilize Kupffer cell membrane, make Ca++ ion channel to open, thus blocked calcium
(endotoxin mainly by stimulating Kupffer cell membrane, activates flow of calcium ions for the TNF-α synthesis that in ion, stream causes and secretion
Release TNF-α).
Lycopene is primarily present in the mature fruit of plant of Solanaceae Fructus Lycopersici esculenti.It is to be found in the plant of nature at present
One of powerful antioxidant.Science proves, singlet oxygen and oxygen-derived free radicals in human body are infringement human body self immune system
Arch-criminal.Lycopene is removed effect of free radical and is outclassed other carotenoid and vitamin E, its singlet-oxygen quenching
Speed constant is 100 times of vitamin E.It can be with effectively preventing because of aging, the various diseases that immunity degradation causes.Kind
Lycopene, by connecting between inducing cell, strengthens the GJIC between normal cell, controls cell growth and Cell differentiation inducing activity presses down
The growth of tumor processed.Lycopene is a kind of low cholesterol agent, and it can suppress macrophage 3-hydroxy-3-methylglutaric acid list acyl auxiliary
Enzyme A, and it is the rate-limiting enzyme of a kind of Biosynthesis of cholesterol.Experiment finds, adds Fructus Lycopersici esculenti in the medium cultivating macrophage
After red pigment, its cholesterol biosynthesis reduces, and lycopene also increases macrophage low density lipoprotein, LDL (LDL) receptor active simultaneously.
Experiment it is also shown that human body in 3 months every day supplement 60mg lycopene, can reduce by the kytoplasm LDL-C concentration of 14%.
The above-mentioned biological characteristics of lycopene determines it to be had antioxidation, mutation inhibiting, reduction nucleic acid damaging, reduces cardiovascular disease
The plurality of health care functions such as disease and prophylaxis of cancer.
For theory of Chinese medical science, the patient of various acute and chronic hepatitis, often show as delay, deadlocked, obstinate, difficult more etc.
Damp and hot disease feature, therefore, " hepatitis virus " is referred to as " epidemic disease caused by damp-heat pathogen poison " or " noxious dampness " by most scholars.From Chinese medical discrimination
From the point of view of, viral hepatitis belongs to " epidemic febrile disease " category, and with damp and hot as cause, liver spleen is with sick.Pathogenesis change mainly toxic dampness and heat accumulates
Knot taste, are stranded and hold back liver and gall, so that transporting and transforming function of the spleen and stomach loses strong, irritability catharsis is not normal.Its mechanism is: epidemic disease caused by damp-heat pathogen poison sustainable existence body
In, damp and hot gradually being goed deep into blood system by edema caused by disorder of QI, no matter weight in wet base, thermogravimetric or damp and hot lay equal stress on, damp and hot long bridle all may result in blood stasis, by
In dampneee being viscous and lingering, damp and hot the most easily block mechanism of qi, the stagnation of QI then blood stasis;Wet easy heat-transformation, the easy stasis of blood of heat in blood then blood are stagnant, and then are formed damp and hot
Ecchymosis is demonstrate,proved.If damp and hot stifling, liver and gall are lost and are let out, the bile flowing outside the biliary passages and excessive skin, then occur that icteric sclera, skin be yellow, yellow urine.
Clinical liver disease is observed it will be seen that in different types of liver disease state of an illness chronicity, worsening, activeness stage, patient often shows as hepatic region
Scorching hot distending pain or stomachache, painful area fixes, dry mouth with bitter taste, is not intended to polydipsia, icteric sclera, color of the skin being yellow as peel of orange, and urine is turned to be yellow,
Even such as strong tea sample, feeling of oppression and fullness in the chest and epigastrium or distending pain, have blood in stool, liver palm, red thread or petechia, ecchymosis, yellowish fur, tongue seen from skin
The performances such as matter is dark red, the profound cunning of arteries and veins, hepatosplenomegaly, all can belong to hot and humid ecchymosis and become trouble mutually.The pathology that various acute, chronic hepatitis relate to
Factor mainly includes wet, hot, strongly fragrant, the stasis of blood, poison etc., and its pathogenic process shows as retention of damp-heat in the interior → fire-transformation → wine poison → blood stasis → heresy
The disease conversion characteristic that poison wound is positive.Therefore, the damp and hot initiating agent being hepatopathy and falling ill, hot and humid ecchymosis is tied in incidence of hepatitis mutually
Thimble saves.Wet severe one, indigestion and loss of appetite, detest greasy, heaviness of the head as if it were tightly bandaged, limbs are heavy, abdominal distention loose stool, white and greasy fur, rolling pulse;Thermogravimetric
Person, thirst and liking drink, oliguria with reddish urine, constipation, can have heating, yellowish fur, rapid pulse;Damp and hot and severe one, both symptoms
Double see.
Li Dong Yuan is pointed out: " abundance of vigour, is all filled by QI of the spleen and stomach, then can nourish vigour ", highlights taste to vigour
The effect of supplementing nutrition.Whether " congenital essence " or " acquired essence ", it is required for taste and nutrition, ability are provided continuously
Contain and do not wane, being normally carried out of the activity that sustains life.Taste maintenance is the most important thing of health preserving as can be seen here.
In this prescription, Radix Puerariae and Herba Taraxaci are monarch drug, and the cause of hepatopathy is alleviated and eliminated to heat-clearing and toxic substances removing pathogenic fire reducing from root;It is aided with
Herba Cichorii is assistant officer's medicine, further depressed liver-energy dispersing and function of gallbladder promoting, main catharsis, helps the damp and hot discharge in patient body;Poria is adjuvant drug, eliminating dampness and diuresis,
Assist a ruler in governing a country assistant officer's medicine dehumidifying;Radix Glycyrrhizae, for making medicine, plays the effect relaxing each property of medicine, furthermore, Radix Glycyrrhizae invigorating the spleen and replenishing QI, relieving spasm to stop pain, slow
Solve pain when patient's disease is sent out, supplement my vigour simultaneously, help patients ' recovery.Soybean oligo saccharide, glycine can reduce blood
Clearing gallbladder sterin, can prevent and treat blood clotting, thrombosis.Soybean oligo saccharide can also reduce internal toxic metabolite material and produce, and alleviates liver detoxification
Burden.Little molecule soy peptide powder easily absorbs, help patient supplement high quality protein, beneficially pathological changes hepatocyte repair with again
Raw.Poria, lycopene can reduce interior free yl, enhancing human body immunity power.
The prescription of the present invention integrate heat clearing away, dampness removing, removing heat from blood, invigorate blood circulation, all methods such as removing toxic substances are treated, and are effectively improved patient
Damp and hot disease.Meanwhile, by being in harmonious proportion patient's taste and liver and gall, metabolic function is improved, beneficially the recovery of patient's vigour.3rd,
By supplementary high quality protein, patient is helped to repair the hepatocyte of pathological changes.4th, by improving patient's autoimmunity, strengthen
Resistance against diseases and raising rehabilitation ability.
Prescription of the present invention, by using the Chinese medicine material of natural Medicine Food Homology, is aided with nutrient substance, the compatibility of science, promotes medicine
Thing is drained, and the liver protecting improves stem cell function, the problem of fatty liver and associated metabolic system is carried out Non-medicine intervention, food
Medicine homology avoids the secondary injury that liver is caused by Drug therapy, reaches the effect of " liver heat removing hepatoprotective not impairing the liver ".
Specific embodiment mode
Below in conjunction with specific embodiment, the present invention will be further described.
Embodiment 1
A kind of detoxicating prophylactic treatment liver and compositions of correlated metabolism diseases of protecting the liver, according to the mass fraction, its major ingredient is Radix Puerariae
200 parts, 200 parts of Poria, Herba Taraxaci 50 parts, 40 parts of Radix Glycyrrhizae, Herba Cichorii 160 parts, soybean oligo saccharide 5 parts, soy peptide powder
10 parts, glycine 5 parts, lycopene 2 parts;Its adjuvant is edible corn starch 5 parts, sodium carboxymethyl cellulose 4 parts.
Wherein, Radix Puerariae, Herba Taraxaci are handled as follows:
(1) Radix Puerariae, Herba Taraxaci are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20 mesh aperture sieve;
(2) weighing Radix Puerariae coarse powder and Herba Taraxaci coarse powder, the ratio with solid-liquid ratio as 1:5 adds the ethanol water that volumetric concentration is 40%
Solution, ultrasonic immersing 6h at a temperature of 40 DEG C, filters;
(3) taking filtering residue, it is the ethanol water of 40% that the ratio with solid-liquid ratio as 1:1 adds volumetric concentration, at a temperature of 40 DEG C
Ultrasonic immersing 6h, filters, and twice filtrate is merged, is evaporated to without ethanol;
(4) solution is dialysed, take filtrate and be spray-dried, obtain Radix Puerariae, Herba Taraxaci extract.
Poria, Radix Glycyrrhizae are handled as follows:
(1) Poria, Radix Glycyrrhizae are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20 mesh aperture sieve;
(2) weighing Poria coarse powder and Radix Glycyrrhizae coarse powder, the ratio with solid-liquid ratio as 1:5 adds pure water, heated at constant temperature leaching at 45 DEG C
Bubble 20min, heated and boiled 20min, filters;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:1 adds pure water, and at 45 DEG C, heated at constant temperature soaks 20min, and heating is boiled
Boiling 20min, filters, and continues to be heated to boiling, and is stirred continuously, make Poria, Radix Glycyrrhizae fluidextract after twice filtrate being merged
Standby.
Herba Cichorii is handled as follows:
(1) Herba Cichorii is cleaned, pulverize after cleaning, coarse powder is crossed 20 mesh aperture sieve;
(2) joining in container by Herba Cichorii coarse powder, the ratio with solid-liquid ratio as 1:0.8 adds 70% ethanol solution, stirs,
Moistening airtight standing 1h;
(3) the Herba Cichorii coarse powder after infiltration is transferred in percolator, suitably presses, after dipping 24h, with the speed of 1ml/min
Collect extracting solution;
(4) by extracting solution concentrating under reduced pressure, until without ethanol;
(5) concentrate, be dried, obtain Herba Cichorii extract.
The preparation technology of the compositions protecting the liver detoxicating prophylactic treatment liver and correlated metabolism diseases of the present invention, comprises the steps:
(1) weigh: weigh soybean oligo saccharide 5 parts, soy peptide powder 10 parts, glycine 5 parts, lycopene 2 parts, eat
Corn starch 5 parts, sodium carboxymethyl cellulose 4 parts, individually deposit;
(2) pelletize: Radix Puerariae and Herba Taraxaci extract, Poria cocos and liquorice fluid extract, Herba Cichorii extract move into efficient wet granulator
After middle mix homogeneously, add soy peptide powder, glycine, lycopene, sodium carboxymethyl cellulose, again mix homogeneously, make
Granule;
(3) cladding: add soybean oligo saccharide, edible corn starch after step (2) makes granule, by soybean oligo saccharide
It is evenly coated at granule appearance with edible corn starch;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Embodiment 2
A kind of detoxicating prophylactic treatment liver and compositions of correlated metabolism diseases of protecting the liver, according to the mass fraction, its major ingredient is Radix Puerariae
250 parts, 220 parts of Poria, Herba Taraxaci 60 parts, 50 parts of Radix Glycyrrhizae, Herba Cichorii 180 parts, soybean oligo saccharide 6 parts, soy peptide powder
15 parts, glycine 8 parts, lycopene 3 parts;Its adjuvant is edible corn starch 6 parts, sodium carboxymethyl cellulose 6 parts.
Wherein, Radix Puerariae, Herba Taraxaci are handled as follows:
(1) Radix Puerariae, Herba Taraxaci are cleaned, pulverize respectively after cleaning, coarse powder is crossed 40 mesh aperture sieve;
(2) weighing Radix Puerariae coarse powder and Herba Taraxaci coarse powder, it is the ethanol of 60% that the ratio with solid-liquid ratio as 1:10 adds volumetric concentration
Aqueous solution, ultrasonic immersing 8h at a temperature of 60 DEG C, filters;
(3) taking filtering residue, it is the ethanol water of 60% that the ratio with solid-liquid ratio as 1:2 adds volumetric concentration, at a temperature of 60 DEG C
Ultrasonic immersing 8h, filters, and twice filtrate is merged, is evaporated to without ethanol;
(4) solution is dialysed, take filtrate and be spray-dried, obtain Radix Puerariae, Herba Taraxaci extract.
Poria, Radix Glycyrrhizae are handled as follows:
(1) Poria, Radix Glycyrrhizae are cleaned, pulverize respectively after cleaning, coarse powder is crossed 40 mesh aperture sieve;
(2) weighing Poria coarse powder and Radix Glycyrrhizae coarse powder, the ratio with solid-liquid ratio as 1:8 adds pure water, heated at constant temperature leaching at 65 DEG C
Bubble 30min, heated and boiled 30min, filters;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:2 adds pure water, and at 65 DEG C, heated at constant temperature soaks 30min, and heating is boiled
Boiling 30min, filters, and continues to be heated to boiling, and is stirred continuously, make Poria, Radix Glycyrrhizae fluidextract after twice filtrate being merged
Standby.
Herba Cichorii is handled as follows:
(1) Herba Cichorii is cleaned, pulverize after cleaning, coarse powder is crossed 40 mesh aperture sieve;
(2) joining in container by Herba Cichorii coarse powder, the ratio with solid-liquid ratio as 1:1 adds 70% ethanol solution, stirs,
Moistening airtight standing 2h;
(3) the Herba Cichorii coarse powder after infiltration is transferred in percolator, suitably presses, after dipping 36h, with the speed of 3ml/min
Collect extracting solution;
(4) by extracting solution concentrating under reduced pressure, until without ethanol;
(5) concentrate, be dried, obtain Herba Cichorii extract.
The preparation technology of the compositions protecting the liver detoxicating prophylactic treatment liver and correlated metabolism diseases of the present invention, comprises the steps:
(1) weigh: weigh soybean oligo saccharide 6 parts, soy peptide powder 15 parts, glycine 8 parts, lycopene 3 parts, eat
Corn starch 6 parts, sodium carboxymethyl cellulose 6 parts, individually deposit;
(2) pelletize: Radix Puerariae and Herba Taraxaci extract, Poria cocos and liquorice fluid extract, Herba Cichorii extract move into efficient wet granulator
After middle mix homogeneously, add soy peptide powder, glycine, lycopene, sodium carboxymethyl cellulose, again mix homogeneously, make
Granule;
(3) cladding: add soybean oligo saccharide, edible corn starch after step (2) makes granule, by soybean oligo saccharide
It is evenly coated at granule appearance with edible corn starch;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Embodiment 3
A kind of detoxicating prophylactic treatment liver and compositions of correlated metabolism diseases of protecting the liver, according to the mass fraction, its major ingredient is Radix Puerariae
225 parts, 210 parts of Poria, Herba Taraxaci 55 parts, 45 parts of Radix Glycyrrhizae, Herba Cichorii 170 parts, soybean oligo saccharide 5 parts, soy peptide powder
12 parts, glycine 6 parts, lycopene 3 parts;Its adjuvant is edible corn starch 5 parts, sodium carboxymethyl cellulose 5 parts.
Wherein, Radix Puerariae, Herba Taraxaci are handled as follows:
(1) Radix Puerariae, Herba Taraxaci are cleaned, pulverize respectively after cleaning, coarse powder is crossed 30 mesh aperture sieve;
(2) weighing Radix Puerariae coarse powder and Herba Taraxaci coarse powder, the ratio with solid-liquid ratio as 1:7 adds the ethanol water that volumetric concentration is 50%
Solution, ultrasonic immersing 7h at a temperature of 50 DEG C, filters;
(3) taking filtering residue, it is the ethanol water of 50% that the ratio with solid-liquid ratio as 1:1.5 adds volumetric concentration, the temperature of 50 DEG C
Lower ultrasonic immersing 7h, filters, and twice filtrate is merged, is evaporated to without ethanol;
(4) solution is dialysed, take filtrate and be spray-dried, obtain Radix Puerariae, Herba Taraxaci extract.
Poria, Radix Glycyrrhizae are handled as follows:
(1) Poria, Radix Glycyrrhizae are cleaned, pulverize respectively after cleaning, coarse powder is crossed 30 mesh aperture sieve;
(2) weighing Poria coarse powder and Radix Glycyrrhizae coarse powder, the ratio with solid-liquid ratio as 1:7 adds pure water, heated at constant temperature leaching at 50 DEG C
Bubble 25min, heated and boiled 25min, filters;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:1.5 adds pure water, and at 50 DEG C, heated at constant temperature soaks 25min, heating
Boil 25min, filter, continue to be heated to boiling after twice filtrate being merged, and be stirred continuously, make Poria, Radix Glycyrrhizae stream leaching
Cream is standby.
Herba Cichorii is handled as follows:
(1) Herba Cichorii is cleaned, pulverize after cleaning, coarse powder is crossed 30 mesh aperture sieve;
(2) joining in container by Herba Cichorii coarse powder, the ratio with solid-liquid ratio as 1:0.9 adds 70% ethanol solution, stirs,
Moistening airtight standing 1.5h;
(3) the Herba Cichorii coarse powder after infiltration is transferred in percolator, suitably presses, after dipping 30h, with the speed of 2ml/min
Collect extracting solution;
(4) by extracting solution concentrating under reduced pressure, until without ethanol;
(5) concentrate, be dried, obtain Herba Cichorii extract.
The preparation technology of the compositions protecting the liver detoxicating prophylactic treatment liver and correlated metabolism diseases of the present invention, comprises the steps:
(1) weigh: weigh soybean oligo saccharide, soy peptide powder, glycine, lycopene, edible corn starch, carboxymethyl fibre
Dimension element sodium, individually deposits;
(2) pelletize: Radix Puerariae and Herba Taraxaci extract, Poria cocos and liquorice fluid extract, Herba Cichorii extract move into efficient wet granulator
After middle mix homogeneously, add soy peptide powder, glycine, lycopene, sodium carboxymethyl cellulose, again mix homogeneously, make
Granule;
(3) cladding: add soybean oligo saccharide, edible corn starch after step (2) makes granule, by soybean oligo saccharide
It is evenly coated at granule appearance with edible corn starch;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule dries
Dry;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Carrying out effect experimental with the compositions that prescription described in embodiment 3 and preparation method prepare, specific experiment is as follows.
1, zoopery A
The preparation of experiment reagent: take the compositions that the prescription with embodiment 3 and preparation method prepare, dissolves after pulverizing, joins respectively
Make 5,10, the solution of 15mg/ml, now with the current.
Animal packet and model are set up: Normal male mice body weight 18-22g, are divided into 3 groups, and often group 12, is divided into normal control
Group, ethanol feed group, embodiment 3 prescriptions+ethanol feed group.Ethanol feed group mice feed every day ethanol 1 time, 5g/kg body
Weight;Embodiment 3 prescriptions+ethanol feed group, at feed ethanol first 1 hour, the composition solution of feed 0.2mL variable concentrations,
Then feed ethanol 5g/kg;Normal group gives equal-volume (0.2mL) normal saline, continuous gavage 2 weeks.Take blood, point
Standby from serum.
Measure GSH content and liver tissue homogenate's lipid peroxide (TBARS) in mitochondrion: put to death by the method for cervical dislocation
White mice, cuts rapidly abdominal part open and takes out liver, prepares mitochondrion and liver tissue homogenate measures GSH content and hepatic tissue in mitochondrion
Homogenate lipid peroxide (TBARS).The results are shown in Table 1.
The impact of hepatic injury mice ALT, GSH and TBARS that ethanol is induced by table 1 compositions
Note:※※Compare with Normal group: p < 0.001;△△Compare with ethanol group: p < 0.001;△P < 0.05
The above results shows, this prescription has the anti-oxidation protection liver effect of highly significant.After ethanol feed 2 weeks, Mouse Liver line
Plastochondria GSH content extremely reduces, and lipid peroxide growing amount (TBARS) significantly raises, and ALT significantly raises, embodiment
3 prescriptions+ethanol feed group feed after 2 weeks mitochondrion GSH similar with Normal group content, TBARS growing amount is slightly above normal
Comparison, ALT the most slightly raises.And dosage is the highest, effect is the best.
2, zoopery B
The preparation of experiment reagent: take the compositions that the prescription with embodiment 3 and preparation method prepare, dissolves after pulverizing, joins respectively
Make 50,100, the solution of 150mg/ml, now with the current.
Animal packet and model are set up: normal male SD rat, body weight 200-220g, are divided into 4 groups, Normal group, prescription
Dosage group, prescription low dose group in high dose group, prescription, filter solution through microfilter before injection, inject 0.2mL every day
Solution;Matched group lumbar injection every day equal-volume normal saline 0.2mL, successive administration 14 days.
Measure rat blood serum ALT and TNF-α changes of contents: after 14 days, rat tail vein injects lipopolysaccharide (LPS) 2mg/kg
Body weight, takes blood after 120 minutes, separate serum, measures rat blood serum ALT and TNF-α changes of contents.The results are shown in Table 2.
Rat ALT that LPS is induced by table 2 compositions and the impact of TNF-α content
Group | ALT(U/L) | TNF-α(U/mL) |
Normal group | 873.7±112.2 | 7035.2±430.7 |
High dose group | 59.48±7.6※※ | 516.3±89.5※※ |
Middle dosage group | 87.4±9.6※ | 612.5±76.6※ |
Low dose group | 102.31±6.3 | 806.1±13.9 |
Note:※※Compare with matched group: P < 0.001,※P < 0.05
Above-mentioned test result indicate that, the rat TNF-α that LPS is induced by the present composition has pole to significantly inhibit effect, LPS
Can significantly raise control rats ALT, and experimental group ALT the most slightly raises, dosage is the highest simultaneously, and inhibition is the best.Knot
Fruit explanation: the hepatic injury of present composition induced by endotoxin induction has extremely strong protective effect.
3, human experimentation
Object of study and packet: from certain city's endocrine diabetes hospital, consulting patients in out-patient department and Physical Examination crowd, choosing
Select through color doppler sonography Diagnosis of Fatty patient 862 example (male 558 examples, female 304 example) 52 ± 19 years old mean age (40-71
Year) with reference to " Chinese Medical Association's hepatology branch alcoholic fatty liver and non-alcoholic fatty liver disease diagnostic criteria " by 862 example fat
Fat hepatopath is divided into 2 groups: (1) alcoholic fatty liver group (290 example), (2) non-alcoholic fatty liver disease group (572 example).
Observation item: to all fatty liver experimenters (treatment group and matched group) all through the medical speciality technical staff of special training
Be responsible for investigating, inquire and record, age, sex, occupation, drink, diabetes, hypertension and history of medications
Deng.It is fully completed following physical examination and laboratory and color doppler sonography inspection.
(1) clinical examination
Measure the height (centimetre, cm) of examinee, empty body weight (kilogram, kg) with desk-top balance, during measurement examinee should take off one's shoes,
Raise one's hat, unlined garment, unlined trousers measurement.Waistline and hip circumference (centimetre, cm) is measured with tape.The measurement of waistline is with costal margin and crista iliaca
Upper intermarginal Xiao Zhou footpath is as the criterion, and through pubic symphysis, both sides through greater trochanter of femur before the measurement of hip circumference, the most prominent by buttocks
Going out position is standard, calculates Body Mass Index (BMI)=body weight (Kg)/height (m) 2, waist-to-hipratio (WH)=waistline (cm)/hip circumference
(cm).The measuring method of blood pressure (BP) uses National Sampled Study on Hypertension in China unified standard, uses hydrargyrum to lean on formula sphygomanometer without exception.
Examinee needs rest 5 minutes of sitting quietly before measuring, then takes seat, measures right upper extremity blood pressure.Shrink pressure (SBP) to hear
1st phase heart sound is as the criterion, and diastolic pressure (DBP) is as the criterion with the 5th phase disappearance sound.It is spaced 2 minutes, measures continuously twice, take
Its meansigma methods.The front weighing machine of measurement, sphygomanometer are the most corrected.More than operation is special messenger's special plane and carries out.
(2) lab testing
Full-fledged research object fasting the most overnight 12 hours before treatment, blood drawing on an empty stomach in secondary everyday early morning, employing full-automatic biochemical instrument,
Survey fasting glucose (FBG), cholesterol (TC), triglyceride (TG), HDL-C (HDL-C), low close
Degree lipoprotein cholesterol (LDL-C), gamma glutamyl transpeptidase (GTT), glutamate pyruvate transaminase (AST), glutamic oxaloacetic transaminase, GOT (ALT),
Blood urea nitrogen (BUN), creatinine (Cr), uric acid (UA) etc..Johnson & Johnson of U.S. full-automatic dry chemistry instrument is used to measure tumor necrosis factor
(TNF-α), C reactive protein (CRP).
(3) liver color Doppler checks
Liver color ultrasound uses U.S.'s PHILIPS M2540A type color Doppler ultrasound, frequency 10MHz, fixing special messenger's operation.
Experimenter's fasting overnight 12 hours, in early morning on the same day, clinostatism of making even, transverse scan combines with vertical disconnected scanning, clearly shows that liver
Structure.
Therapeutic Method: all object of study all started to take the present composition the same day, 0.65g/ sheet, 4 pieces/times, 3 times/day,
Continuous use 8-10 week.After taking medicine, 4-5 and 8-10 week checks These parameters and lab testing respectively, observes and notes down patient
To drug reaction etc..
Observation index and the standard of curative effect evaluation: extract limosis vein blood before and after treatment respectively, measure fasting glucose (FBG), gallbladder solid
Alcohol (TC), triglyceride (TG), HDL-C (HDL-C), low-density lipoprotein cholesterol (LDL-C),
Gamma glutamyl transpeptidase (GTT), glutamate pyruvate transaminase (AST), glutamic oxaloacetic transaminase, GOT (ALT), blood urea nitrogen (BUN), creatinine (Cr),
Uric acid (UA), tumor necrosis factor (TNF-α), C reactive protein (CRP), measure blood pressure, and row liver color Doppler checks,
Being carried out by same position doctor before and after treatment, paired observation ultrasonography of liver changes.
(1) curing: symptom, sign disappear substantially, liver function indices recovers normal, and super liver ultrasonogram recovers normal.
(2) effective: symptom, sign are obviously improved, liver function recovery is normal or declines more than 50%, and ultrasonic liver picture figure is obvious
Improve (declining 1 grade), the indices at least 1 such as blood fat, uric acid (UA), tumor necrosis factor (TNF-α)
More than recover normal or decline more than 50%;
(3) effective: to cure and effective person is all judged to effectively;
(4) invalid: symptom, sign are not improved, liver function, blood fat indices decline less than 20%, B ultrasonic liver acoustic image
Figure is without significant change.
Interpretation of result and statistical procedures: statistical analysis uses spss11.5 software kit to carry out, group difference uses t inspection,
Multiple sample averages compare uses variance analysis.Every result see table.
Table 3 compositions general Index Influence clinical to Patients with Fatty Liver
Project | Before treatment | After treatment | P value |
Number of cases (male/female) | 862(558/304) | 862(558/304) | |
Age | 52.10±12.19 | 52.10±12.19 | |
Height (m) | 1.68±0.87 | 1.68±0.87 | |
Body weight (Kg) | 78.38±14.09 | 78.05±13.28 | 0.56 |
Body Mass Index (BMI) | 27.75±3.51 | 27.65±3.27 | 0.87 |
Waistline (cm) | 94.86±7.73 | 94.51±6.88 | 0.70 |
Hip circumference (cm) | 101.28±5.57 | 100.95±5.38 | 0.94 |
Waist/buttocks | 0.94±0.06 | 0.94±0.05 | 0.825 |
Shrink pressure (mmHg) | 130.31±15.56 | 129.60±14.86 | 0.410 |
Diastolic pressure (mmHg) | 83.73±7.60 | 83.15±7.42 | 0.447 |
Body fat content (%) | 34.52±3.83 | 32.45±3.47 | 0.56 |
The above results shows, after treatment, the body weight of patient, BMI, waistline, hip circumference have declined before relatively treating, but statistics
Learn difference not notable, and body fat content is decreased obviously.
The impact on Patients with Fatty Liver metabolism of table 4 compositions
Project | Before treatment | After treatment | P value |
FBG(mmol/L) | 6.35±2.02 | 6.24±1.71 | 0.583 |
TC(mmol/L) | 5.77±1.41 | 5.36±1.54 | 0.066 |
TG(mmol/L) | 2.62±2.27 | 1.37±0.61 | 0.000* |
LDL(mmol/L) | 3.45±1.63 | 3.51±1.48 | 0.38 |
HDL(mmol/L) | 1.13±0.48 | 1.22±0.46 | 0.365 |
The impact on Patients with Fatty Liver liver function of table 5 compositions
Project | Before treatment | After treatment | P value |
GGT(U/L) | 54.66±21.40 | 34.40±9.81 | 0.000* |
ALT(U/L) | 54.53±24.05 | 33.19±10.33 | 0.000* |
AST(U/L) | 51.08±27.72 | 26.15±9.32 | 0.000* |
The impact on Patients with Fatty Liver renal function of table 6 compositions
Project | Before treatment | After treatment | P value |
BUN(mmol/L) | 5.19±1.51 | 5.17±1.25 | 0.620 |
Cr(umol/L) | 74.80±13.88 | 75.45±17.10 | 0.352 |
UA(umol/L) | 364.2±86.18 | 358.1±62.62 | 0.368 |
The impact on inflammatory cytokine special on Patients with Fatty Liver of table 7 compositions
Project | Before treatment | After treatment | P value |
TNF(pg/ml) | 17.82±6.84 | 9.58±3.17 | 0.000* |
CRP(mg/L) | 3.12±0.91 | 2.42±0.68 | 0.000* |
From above-mentioned serial experiment, the present composition can significantly reduce the inflammation such as ALT, AST level and suppression TNF-α
Sexual cell factor effect, to improving and reverse liver function and intracellular antioxidation and anti-inflammatory effect is very notable, it addition,
The present composition still has reduction body fat content, TC, TG, adjusts and improve metabolism.
Claims (5)
1. one kind protects the liver detoxicating prophylactic treatment liver and the compositions of correlated metabolism diseases, it is characterised in that: according to the mass fraction, its
Major ingredient be Radix Puerariae 200-250 part, Poria 200-220 part, Herba Taraxaci 50-60 part, Radix Glycyrrhizae 40-50 part, Herba Cichorii 160-180 part,
Soybean oligo saccharide 5-6 part, soy peptide powder 10-15 part, glycine 5-8 part, lycopene 2-3 part;Its adjuvant is edible corn
Starch 5-6 part, sodium carboxymethyl cellulose 4-6 part.
The most according to claim 1 protect the liver detoxicating prophylactic treatment liver and the compositions of correlated metabolism diseases, it is characterised in that:
Described Radix Puerariae, Herba Taraxaci are handled as follows:
(1) Radix Puerariae, Herba Taraxaci are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) the Radix Puerariae coarse powder of 200-250 mass fraction and the Herba Taraxaci coarse powder of 50-60 mass fraction are weighed, with solid-liquid ratio as 1:5-10
Ratio add volumetric concentration be the ethanol water of 40-60%, ultrasonic immersing 6-8h at a temperature of 40-60 DEG C, filter;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:1-2 adds the volumetric concentration ethanol water as 40-60%, the temperature of 40-60 DEG C
The lower ultrasonic immersing 6-8h of degree, filters, twice filtrate is merged, be evaporated to without ethanol;
(4) solution is dialysed, take filtrate and be spray-dried, obtain Radix Puerariae, Herba Taraxaci extract.
The most according to claim 1 protect the liver detoxicating prophylactic treatment liver and the compositions of correlated metabolism diseases, it is characterised in that:
Described Poria, Radix Glycyrrhizae are handled as follows:
(1) Poria, Radix Glycyrrhizae are cleaned, pulverize respectively after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) the Poria coarse powder of 200-220 mass parts and the Radix Glycyrrhizae coarse powder of 40-50 mass fraction, the ratio with solid-liquid ratio as 1:5-8 are weighed
Example adds pure water, and at 45-65 DEG C, heated at constant temperature soaks 20-30min, heated and boiled 20-30min, filters;
(3) taking filtering residue, the ratio with solid-liquid ratio as 1:1-2 adds pure water, and at 45-65 DEG C, heated at constant temperature soaks 20-30min, heating
Boil 20-30min, filter, continue to be heated to boiling after twice filtrate being merged, and be stirred continuously, make Poria, Radix Glycyrrhizae stream
Extractum is standby.
The most according to claim 1 protect the liver detoxicating prophylactic treatment liver and the compositions of correlated metabolism diseases, it is characterised in that:
Described Herba Cichorii is handled as follows:
(1) Herba Cichorii is cleaned, pulverize after cleaning, coarse powder is crossed 20-40 mesh aperture sieve;
(2) joining in container by Herba Cichorii coarse powder, the ratio with solid-liquid ratio as 1:0.8-1 adds 70% ethanol solution, stirs,
Moistening airtight standing 1-2h;
(3) the Herba Cichorii coarse powder after infiltration is transferred in percolator, suitably presses, after dipping 24-36h, with the speed of 1-3ml/min
Collect extracting solution;
(4) by extracting solution concentrating under reduced pressure, until without ethanol;
(5) concentrate, be dried, obtain Herba Cichorii extract.
The preparation technology of the compositions protecting the liver detoxicating prophylactic treatment liver and correlated metabolism diseases the most according to claim 1, its
It is characterised by: comprise the steps:
(1) weigh: weigh soybean oligo saccharide 5-6 part, soy peptide powder 10-15 part, glycine 5-8 part, lycopene 2-3 part,
Edible corn starch 5-6 part, sodium carboxymethyl cellulose 4-6 part, individually deposit;
(2) pelletize: Radix Puerariae and Herba Taraxaci extract, Poria cocos and liquorice fluid extract, Herba Cichorii extract move in efficient wet granulator mixed
After closing uniformly, add soy peptide powder, glycine, lycopene, sodium carboxymethyl cellulose, again mix homogeneously, make granule;
(3) cladding: add soybean oligo saccharide, edible corn starch after step (2) makes granule, by soybean oligo saccharide and food
It is evenly coated at granule appearance with corn starch;
(4) it is dried: wet granular is moved into Fast granulate machine dispersion and granulation, then moves in drying and granulating machine dry, until granule is dried;
(5) granulate: dry granule is used Fast granulate machine granulate, is dispersed into uniform granule;
(6) tabletting: granule uses sheeting equipment carry out tabletting;
(7) packaging: using automatic packaging machine packaging, case after luggage box of going forward side by side again, warehouse-in preserves.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610265250.7A CN105727253A (en) | 2016-04-26 | 2016-04-26 | Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610265250.7A CN105727253A (en) | 2016-04-26 | 2016-04-26 | Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105727253A true CN105727253A (en) | 2016-07-06 |
Family
ID=56285631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610265250.7A Pending CN105727253A (en) | 2016-04-26 | 2016-04-26 | Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105727253A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664891A (en) * | 2019-11-20 | 2020-01-10 | 清远创春园食品生产有限公司 | Traditional Chinese medicine composition for clearing hepatobiliary toxin |
CN114343172A (en) * | 2022-01-28 | 2022-04-15 | 特康药业集团有限公司 | Application of traditional Chinese medicine composition in food for improving liver function of chronic liver disease patient, nutrition powder and preparation method |
CN115518132A (en) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | Chinese medicinal compound composition for preventing and treating hyperuricemia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102327259A (en) * | 2011-03-31 | 2012-01-25 | 姜国辉 | Composite biological preparation with obvious chemical hepatic injury protecting function |
-
2016
- 2016-04-26 CN CN201610265250.7A patent/CN105727253A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102327259A (en) * | 2011-03-31 | 2012-01-25 | 姜国辉 | Composite biological preparation with obvious chemical hepatic injury protecting function |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664891A (en) * | 2019-11-20 | 2020-01-10 | 清远创春园食品生产有限公司 | Traditional Chinese medicine composition for clearing hepatobiliary toxin |
CN114343172A (en) * | 2022-01-28 | 2022-04-15 | 特康药业集团有限公司 | Application of traditional Chinese medicine composition in food for improving liver function of chronic liver disease patient, nutrition powder and preparation method |
CN115518132A (en) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | Chinese medicinal compound composition for preventing and treating hyperuricemia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
CN103734428B (en) | A kind of glossy privet fruit health-care tea improving immunity and preparation method thereof | |
CN102784295B (en) | Health-care preparation formula for improving female climacteric syndrome and preparation method of same | |
CN102172269B (en) | Hidegelatin fabricated food with beautification function | |
CN104147132A (en) | Soft gel capable of reducing blood sugar and adjusting insulin secretion and production method | |
CN103405728B (en) | A kind of Chinese medicine composition for the treatment of climacteric syndrome and preparation method thereof | |
CN101972338A (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
CN109550040A (en) | A kind of Chinese medicine peptide composition of strengthen immunity | |
CN104305205B (en) | A kind of Semen Cuscutae oral liquid improving immunity and preparation method thereof | |
CN103859375A (en) | Formula and preparation method of life cultivation and health preservation food helpful for enhancing immunity | |
CN105233100A (en) | Drink for treating diabetes and preparation method thereof | |
CN105727253A (en) | Composition for protecting liver, clearing away toxic materials, preventing and treating liver and related metabolic diseases and preparation method thereof | |
CN106212614A (en) | A kind of cookies of early prevention and treatment type 2 diabetes mellitus and preparation method thereof | |
CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
CN108066712A (en) | A kind of benefiting qi and nourishing blood Chinese medicine composition | |
CN104286864B (en) | A kind of semen astragali complanati oral liquid improving immunity and preparation method thereof | |
CN109527577A (en) | A kind of composition with sobering up and liver protecting functions | |
CN107998366A (en) | It is a kind of suitable for Chinese medicine composition of puerpera's lactagogue at initial stage in postpartum and preparation method thereof | |
CN103340991B (en) | Oral liquid for nursing diabetics and preparation method thereof | |
CN106822660A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
CN106036906A (en) | Selenium-enriched kudzu root guilinggao for nourishing blood and calming nerves and preparation method thereof | |
CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
CN101884739B (en) | Food therapy preparation for preventing and treating diabetes based on theories of preventive treatment of disease and medicine food homology | |
CN111264866A (en) | Mammary gland fibroma medical formula food and preparation method thereof | |
CN104814372A (en) | Health guiling jelly based on sweet potatoes and preparation method of healthy guiling jelly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |